Phase 3 Myasthenia Gravis Trial, Recruiting (NCT06765161)

Phase 3 Myasthenia Gravis Trial, Recruiting NCT06765161 Sponsor: Clinique Neuro-Outaouais Condition: Myasthenia Gravis

Printed from Voxsanity (voxsanity.com.au) — NCT06765161 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myasthenia Gravis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are willing and able to sign a consent form to take part in the study.
You are between 18 and 80 years old.
You have been diagnosed with Myasthenia Gravis and have tested positive for acetylcholine receptor antibodies.
Your condition has been stable for at least 4 months, meaning your IVIG treatment schedule has not changed and your symptoms have not significantly changed.
You have not had any changes to certain immune-suppressing medications (non-steroidal immunosuppressive treatments) in the past 6 months.
You have not had any changes to steroid medications in the past 3 months.
Your Myasthenia Gravis diagnosis was confirmed by an abnormal nerve transmission test, or you have a history of responding to a specific type of medication called an AChE inhibitor.
You have been receiving regular IVIG (intravenous immunoglobulin) infusions for Myasthenia Gravis for at least one year.

Who may not be able to join:

You have received Rituximab, Eculizumab, or plasma exchange treatment within the past 6 months.
You have had thymus gland surgery (thymectomy) within the past 3 months.
You currently have active Hepatitis B, Hepatitis C, HIV, tuberculosis (active or untreated), or any other significant active infection.
Your blood test shows low levels of a certain immune protein (IgG below 6.0g/L), or you have a history of chronically low levels of this protein for any reason.
You are pregnant or planning to become pregnant within the next 6 months.
You have serious kidney problems (confirm with trial site if unsure about your kidney function).
The trial doctor believes, for any reason, that it would not be appropriate for you to take part.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: François Jacques, Doctor, Clinique Neuro-Outaouais

Phone: 819-777-2500

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06765161

Sponsor: Clinique Neuro-Outaouais

Phase: Phase 3

Status: Recruiting

Condition: Myasthenia Gravis

Trial contact: 819-777-2500

More information: https://clinicaltrials.gov/study/NCT06765161

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are willing and able to sign a consent form to take part in the study.
You are between 18 and 80 years old.
You have been diagnosed with Myasthenia Gravis and have tested positive for acetylcholine receptor antibodies.
Your condition has been stable for at least 4 months, meaning your IVIG treatment schedule has not changed and your symptoms have not significantly changed.
You have not had any changes to certain immune-suppressing medications (non-steroidal immunosuppressive treatments) in the past 6 months.
You have not had any changes to steroid medications in the past 3 months.
Your Myasthenia Gravis diagnosis was confirmed by an abnormal nerve transmission test, or you have a history of responding to a specific type of medication called an AChE inhibitor.
You have been receiving regular IVIG (intravenous immunoglobulin) infusions for Myasthenia Gravis for at least one year.

Who may not be able to join:

You have received Rituximab, Eculizumab, or plasma exchange treatment within the past 6 months.
You have had thymus gland surgery (thymectomy) within the past 3 months.
You currently have active Hepatitis B, Hepatitis C, HIV, tuberculosis (active or untreated), or any other significant active infection.
Your blood test shows low levels of a certain immune protein (IgG below 6.0g/L), or you have a history of chronically low levels of this protein for any reason.
You are pregnant or planning to become pregnant within the next 6 months.
You have serious kidney problems (confirm with trial site if unsure about your kidney function).
The trial doctor believes, for any reason, that it would not be appropriate for you to take part.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Clinique Neuro-Outaouais

Registry

ClinicalTrials.gov

Start date

6 February 2025

Est. completion

6 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

MG-ADL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov